ArticleFrontiers in oncology2026
Interpretable ADC-based radiomics models for differentiating hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop interpretable machine learning (ML) models using apparent diffusion coefficient (ADC) radiomics to differentiate hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC). Methods: Radiomic features were extracted from ADC maps of 83 pathologically confirmed HCC and 46 pathologically confirmed ICC patients who underwent MRI examinations. The least absolute shrinkage and selection operator (LASSO) method selected essential features for five ML models: logistic regression (LR), random forest (RF), gaussian naive bayes (GNB), support vector machine (SVM), and k-nearest neighbors (kNN). external validation was performed using 20 HCC and 20 ICC cases from the cancer imaging archive (TCIA) public database. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, accuracy, F1 score, calibration plots, and decision curve analysis (DCA). The best-performing model was interpreted using shapley additive explanations (SHAP). Results: LASSO selected eight features. The models achieved training AUROCs of 0.84-0.95 and internal validation AUROCs of 0.78-0.91. The LR model demonstrated superior performance (training AUROC: 0.95; internal validation AUROC: 0.91; external validation AUROC: 0.85). Moreover, calibration plots and DCA confirmed that this model exhibited the best calibration and clinical utility. SHAP identified wavelet-LLL-firstorder-RootMeanSquared as the most impactful feature. Conclusions: The ADC-based LR model robustly differentiates HCC from ICC, with validated generalizability using public data, offering a promising non-invasive clinical tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.